Investor Presentaiton

Differentiated Platforms: Significantly expand the opportunity in Targeted Protein Degradation & Cell Therapy Opportunity for Targeted Protein Degradation Positioned to deliver ~4 INDS annually ☑ Hematology Oncology And expand targets to new therapeutic areas: Immunology Neuroscience Abecma [idecabtagene vicleucel) First-in-Class anti-BCMA SUSPENSION FOR VINFUSION Waves of agents expected to launch over time: Building on Our Leadership in Cell Therapy Today Breyanzi (lisocabtagene maraleucel) SUSPENSION FOR IV INFUSION Best-in-Class anti-CD19 Future GPRC5D CAR T CD19 NEX T BCMA X GPRC5D dual binding CAR Innovative Technologies (e.g., allogeneic) Expansion into Immunology: Starting with CD19 NEX T1 Others Severe, refractory lupus AR LDD Other -3x MS golcadomide Multiple Sclerosis mezigdomide SLE iberdomide Other diseases with high unmet need LBCL Heme Malignancy B-cell Mediated Diseases 1.2023 estimates from Decision Resource Group & BMS Internal Analysis; represents U.S. total diagnosed prevalence Ill Bristol Myers Squibb™ Not for Product Promotional Use 11

View entire presentation